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Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by progressive 
neuropathology and cognitive decline. We describe a cross-tissue analysis of methylomic variation 
in AD using samples from three independent human post-mortem brain cohorts. We identify a 
differentially methylated region in the ankyrin 1 (ANK1) gene that is associated with 
neuropathology in the entorhinal cortex, a primary site of AD manifestation. This region was 
confirmed as significantly hypermethylated in two other cortical regions (superior temporal gyrus 
and prefrontal cortex) but not in the cerebellum, a region largely protected from 
neurodegeneration in AD, nor whole blood obtained pre-mortem, from the same individuals. 
Neuropathology-associated ANK1 hypermethylation was subsequently confirmed in cortical 
samples from three independent brain cohorts. This study represents the first epigenome-wide 
association study (EWAS) of AD employing a sequential replication design across multiple 
tissues, and highlights the power of this approach for identifying methylomic variation associated 
with complex disease.
Alzheimer’s disease (AD) contributes significantly to the global burden of disease affecting 
in excess of 26 million people worldwide1,2. The pathogenesis associated with AD is 
characterized by the accumulation of amyloid plaques, tangles of intracellular 
hyperphosphorylated tau, gliosis, synaptic dysfunction and eventually cell death3,4. 
Although the neuropathological manifestation of AD is well characterized in post-mortem 
brain, little is known about the underlying risk factors or mechanism(s) involved in disease 
progression. Of note, different parts of the brain show differential vulnerability to AD; 
although there is progressive neurodegeneration across the cortex with areas such as the 
entorhinal cortex (EC) being characterized by considerable and early neuropathology, 
regions such as the cerebellum (CER) are relatively resistant to neuronal damage, with little 
or no plaque or neurofibrillary tangle pathology5.
Contemporary research aimed at exploring the etiology of AD has focused primarily on 
DNA sequence variation, with some notable success6. Increasing knowledge about the 
biology of the genome7 also implicates an important role for epigenetic variation in human 
health and disease, and recent methodological advances mean that epigenome-wide 
association studies (EWAS) are now feasible for complex disease phenotypes including 
AD8. Epigenetic epidemiology is a relatively new endeavor, however, and there are 
important considerations regarding study design, tissue-type, analysis strategy and data 
interpretation9,10. Here we describe the first systematic cross-tissue EWAS analysis of DNA 
methylation in AD using a powerful sequential replication design, with the goal of 
identifying disease-associated methylomic variation across pathologically-relevant regions 
of the brain.
The first (‘discovery’) stage of our analysis utilized multiple tissues from donors (N = 117) 
archived in the MRC London Brainbank for Neurodegenerative Disease. From each donor, 
genomic DNA was isolated from four brain regions (EC, superior temporal gyrus (STG), 
prefrontal cortex (PFC) and CER) and, where available, whole blood obtained pre-mortem 
(Supplementary Table S1 and Supplementary Table S2). DNA methylation was quantified 
using the Illumina 450K HumanMethylation array, with pre-processing, normalization and 
stringent quality control undertaken as previously described11 (see Online Methods). Our 
Lunnon et al. Page 2
Nat Neurosci. Author manuscript; available in PMC 2015 April 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
analyses focussed on identifying differentially-methylated positions (DMPs) associated with 
Braak staging, a standardized measure of neurofibrillary tangle burden determined at 
autopsy12, with all analyses controlling for age and sex.
We first assessed DNA methylation differences identified in the EC, given that it is a 
primary and early site of neuropathology in AD5. The top-ranked Braak-associated EC 
DMPs are shown in Table 1 and Supplementary Table S3, with results for the other brain 
regions profiled (STG, PFC, and CER) shown in Supplementary Tables S4–S6. Two of the 
top-ranked EC DMPs (cg11823178, the top-ranked EC DMP, and cg05066959, the fourth-
ranked EC DMP) are located just 91bp away from each other within the ankyrin 1 (ANK1) 
gene on chromosome 8, encoding a brain-expressed protein13 involved in 
compartmentalization of the neuronal plasma membrane14 (Fig. 1a). These DMPs are also 
located proximal to the NKX6-3 gene, encoding a homeodomain transcription factor 
involved in development of the brain15,16. Increased EC DNA methylation at both CpG sites 
is associated with Braak stage (cg11823178: r = 0.47, t(102) = 5.39, P = 4.59E–7; 
cg05066959: r = 0.41, t(102) = 5.37, P = 1.34E–5) (Fig. 1b). As AD is characterized by 
significant neuronal loss we used an in silico algorithm to confirm that the observed 
association is not confounded by differences in neuronal proportions between individuals17; 
both CpG sites remain significantly associated with Braak score after correction for 
estimated cellular heterogeneity (cg11823178: P = 7.09E–7; cg05066959: P = 6.20E–6) 
(Table 1). We used comb-p18 to identify spatially-correlated regions of differential DNA 
methylation, highlighting a Braak-associated DMR spanning these CpG sites (P = 6.04E–7) 
(Supplementary Table S7). Hypermethylation at both DMPs is significantly associated with 
Braak score in the STG (cg11823178: r = 0.37, t(111) = 4.15, P = 6.51E–5; cg05066959: r = 
0.33, t(111) = 3.67, P = 3.78E–4) and the PFC (cg11823178: r = 0.29, t(108) = 3.12, P = 
2.33E–3; cg05066959: r = 0.32, t(108) = 3.52, P = 6.48E–4) (Fig. 1c). In contrast, no 
significant neuropathology-associated hypermethylation is detected at either CpG site in the 
CER (cg11823178: r = 0.01, t(106) = 0.082, P = 0.935; cg05066959: r = −0.08, t(106) = 
0.085, P = 0.395) (Fig. 1d), a region largely protected from neurodegeneration in AD, nor is 
elevated DNA methylation at either site associated with AD diagnosis in whole blood 
collected pre-mortem (data not shown).
Interestingly, we observe significant overlap in Braak-associated DMPs across the three 
cortical regions profiled in the London ‘discovery’ cohort; 38 (permuted P-value < 0.005) 
and 30 (permuted P-value <0.005) of the 100 top-ranked EC probes are significantly 
differentially methylated in the same direction in the STG and PFC, respectively 
(Supplementary Table S8), with a highly significant correlation of top-ranked Braak-
associated DNA methylation scores across these sites (EC vs STG: r = 0.88, P = 6.73E–14; 
EC vs PFC: r = 0.83, P = 8.77E–13). There is, however, a clear distinction between cortical 
regions and CER, with the top-ranked CER DMPs appearing to be more tissue–specific and 
not differentially methylated in cortical regions (permuted P-values for enrichment all > 
0.05), although ~15% of the top-ranked cortical DMPs are differentially methylated in CER 
(permuted P-values all ≤ 0.01), indicating that these represent relatively pervasive AD-
associated changes that are observed across multiple tissues. We subsequently used a meta-
analysis method (see Online Methods) to highlight consistent Braak-associated DNA 
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methylation differences across all three cortical regions in the ‘discovery’ cohort. The top-
ranked cross-cortex DMPs are shown in Table 2 and Supplementary Table S9, with DMRs 
identified using comb-p listed in Supplementary Table S10. Of note, cg11823178 is the most 
significant cross-cortex DMP (Δ = 3.20, Fisher’s P = 3.42E–11, Brown’s P = 1.00E–6), with 
cg05066959 again ranked fourth (Δ = 4.26, Fisher’s P = 1.24E–9, Brown’s P = 6.24E–6) 
(Fig. 1e) and a DMR spanning these probes being associated with neuropathology (Sidak-
corrected P = 3.39E–4) (Supplementary Table S10). Together, these data suggest that 
cortical DNA hypermethylation at the ANK1 locus is robustly associated with AD-related 
neuropathology.
A cortical ‘replication’ dataset was generated using DNA isolated from two regions (STG 
and PFC) obtained from a cohort of brains archived in the Mount Sinai Alzheimer’s Disease 
and Schizophrenia Brain Bank (N = 144) with detailed neuropathology data including Braak 
staging and amyloid burden (see Online Methods)19. Strikingly, Braak-associated DNA 
methylation scores for the 100 top-ranked cross-cortex DMPs identified in the London 
discovery cohort (listed in Supplementary Table 9) are strongly correlated with 
neuropathology-associated differences at the same probes in both cortical regions profiled in 
the Mount Sinai replication cohort (STG Braak score: r = 0.63, P = 2.66E–12; PFC Braak 
score: r = 0.64, P = 6.03E–13; STG amyloid burden: r = 0.46, P = 1.09E–6; PFC amyloid 
burden: r = 0.65, P = 2.87E–13) (see Fig. 2a). Furthermore, increased DNA methylation at 
each of the two ANK1 CpG sites is significantly associated with elevated Braak staging 
(Table 1, Fig. 2b) and amyloid burden (Fig. 2c) in both cortical regions. To further confirm 
the association between cortical ANK1 hypermethylation and neuropathology we used 
bisulfite-pyrosequencing to quantify DNA methylation across an extended region spanning 
eight CpG sites, including cg11823178 and cg05066959 in DNA extracted from a third 
independent collection of matched EC, STG and PFC tissue (N = 62) obtained from the 
Thomas Willis Oxford Brain Collection20 (see Online Methods and Supplementary Table 
S11a). Average DNA methylation across this region was significantly elevated in all three 
cortical regions tested (EC: P = 0.0004; STG: P = 0.0008; PFC: P = 0.014) in affected 
individuals (Supplementary Fig. S1), most notably in the EC where six of the eight CpG 
sites assessed are characterized by significant AD-associated hypermethylation (Fig. 2d). A 
meta-analysis of cg11823178 and cg05066959 across all three independent cohorts confirms 
consistent neuropathology-associated hypermethylation in each of the cortical regions 
assessed (Fig. 2e and Fig. 2f). Further evidence to support our conclusions comes from an 
independent EWAS of AD pathology in 708 cortical samples (De Jager et al., co-submitted 
article21). There is a significant correlation (r = 0.57, P = 1.55E–9) between the DNA 
methylation changes identified in our cross-cortex analyses and neuropathology-associated 
differences at the same probes in the study by De Jager et al. (Fig. 2g)21. Conversely, 
neuropathology-associated DNA methylation scores for top-ranked DMPs in the study of De 
Jager and colleagues are strongly correlated (r = 0.49, P = 7.8E–10) with those observed 
using the cross-cortex model for the same probes in our discovery cohort (Supplementary 
Fig. S2). In particular, De Jager et al. also identify a highly significant association between 
elevated DNA methylation at cg11823178 and cg05066959 and AD-related neuropathology. 
Together, these data provide compelling evidence for an association between ANK1 
hypermethylation and the neuropathological features of AD, specifically in the cortical 
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regions associated with disease manifestation. Although not previously implicated in 
dementia, genetic variation in ANK1 is associated with diabetic phenotypes22–24, an 
interesting observation given the established links between type 2 diabetes and AD25.
ANK1 is a transcriptionally complex gene, with multiple isoforms and several alternative 
promoters identified (Supplementary Fig. S3). Given the established role of DNA 
methylation in regulating isoform-specific gene expression we examined whether AD 
neuropathology was associated with the differential abundance of various ANK1 isoforms in 
the EC using qPCR (see Online Methods). Briefly, three assays with specificity to ANK1 
isoforms i) 1,2,3 and 4, ii) 9, and iii) 5,7 and 10 (Supplementary Table S11b) were used to 
profile 36 EC samples from whom high quality RNA was available (see Supplementary 
Table S2). Our linear model highlighted a significant association (P = 0.04) between the 
abundance of isoforms 5,7 and 10 transcripts and AD-associated neuropathology 
(Supplementary Fig. S4). No significant differences in transcript levels were observed for 
the other two isoform-specific assays (data not shown).
As a definitive diagnosis of AD can only be made via neuropathological examination at 
autopsy, there is considerable interest in the identification of clinical biomarkers that may 
have both diagnostic and prognostic utility during the early stages of the disorder26,27. 
Recent work has identified several transcriptomic blood biomarkers for AD with potential 
clinical utility for the early diagnosis of the disease28–32. In this study we had access to 
matched pre-mortem whole blood DNA for methylomic profiling from a subset of samples 
in the London ‘discovery’ cohort (N=93). Because of the duration elapsed between blood 
sampling and mortality (average = 4.15 +/− 3.00 years), analyses on these data were 
restricted to the identification of DMPs associated with a clinical diagnosis of AD, rather 
than Braak score. We identified a number of AD-associated DMPs (Supplementary Table 
S12) in pre-mortem blood, many in the vicinity of genes of relevance to AD including 
DAPK1 (cg14067233), previously implicated in genetic studies33,34; GAS1 (cg14067233), 
an APP-interacting protein involved in the control of APP maturation and processing35; and 
NDUFS5 (cg17074958), a mitochondrial gene previously shown to be differentially 
expressed in AD blood36. Our data suggest, however, that the top-ranked DMPs in blood are 
distinct to those identified in the brain; there is no significant overlap with either cortex or 
CER (permuted P-values for enrichment in EC = 0.89, PFC = 0.40, STG = 0.45, and CER = 
0.41) suggesting that AD-associated DMPs in blood are unlikely to be directly related to the 
actual neurodegenerative process itself. Using data from our previous independent blood-
based transcriptomic analyses of both AD and mild cognitive impairment (MCI)36, however, 
we observe that 18 of our top-ranked blood DMPs are located in the vicinity of known 
differentially expressed transcripts (Supplementary Table S13). These data suggest that, 
although distinct from AD-associated changes occurring in the brain, many of the AD-
associated DMPs identified in blood prior to death may mediate detectable transcriptomic 
changes and, given the relative stability and ease of profiling DNA modifications compared 
to RNA, have potential utility as diagnostic biomarkers of the disorder.
Definitively distinguishing cause from effect in epigenetic epidemiology is difficult, 
especially for disorders like AD that are manifest in inaccessible tissues such as the brain 
and not amenable to longitudinal study9,10. However, our observation of highly consistent 
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changes across multiple regions of the cortex in several independent sample cohorts 
suggests that the identified loci are directly relevant to the pathogenesis of AD. In this 
regard, the ANK1 DMR reported here, subsequently confirmed in the study by De Jager and 
colleagues21, represents one of the most robust molecular associations with AD yet 
identified. One issue in EWAS analyses using platforms such as the Illumina 450K array 
relates to potential technical artifacts caused by genetic variation, although we are confident 
that the DMPs identified in this study do not result from polymorphisms in (or flanking) the 
assayed CG dinucleotides. We used a stringent two-pronged strategy to exclude these 
effects: i) the direct exclusion of probes known to be affected by common single nucleotide 
polymorphisms (SNPs) and ii) the statistical filtering of extreme sample outliers within 
individual probe data that are frequently caused by rare SNPs (see Online Methods). 
Although this study was unable to explore the extent to which AD-associated variation is 
driven by genetic variation, the role of genetic-epigenetic interactions in complex disease 
represents an important area for further study37. Finally, power calculations for EWAS 
analyses are difficult, especially given the paucity of existing data for brain DNA 
methylation and limited information about the extent of inter-individual variation occurring 
at individual CpG sites. Conventional methods for multiple-test correction such as those 
used in genome-wide association studies (GWAS) are likely to be overly stringent given the 
non-independence of DNA methylation across multiple CpG sites9,1038. Studies 
investigating the role of epigenetic dysfunction in complex brain diseases such as AD are in 
their infancy, and no real precedents have yet been set about the optimal sample-sizes 
needed to detect them9. Our conservative power calculation (see Online Methods), suggests 
we are well-powered to identify relatively small (~5%) DNA methylation differences 
between groups for the majority of probes on the Illumina 450K array. More importantly, 
our study represents the largest cross-tissue study of AD using DNA from both affected and 
unaffected brain regions, and the first to employ a sequential replication design 
incorporating independent study cohorts and two independent technologies (Illumina 450K 
array and bisulfite–pyrosequencing). The striking overlap between DMPs identified across 
our sample cohorts (Fig. 2a), and with those identified by De Jager et al. (Fig. 2g and 
Supplementary Fig. S2), suggests our study is adequately powered to detect robust AD-
associated differences that can be replicated in other studies.
In summary, our data provide evidence for extensive differences in DNA methylation across 
brain regions in AD. Our analyses of multiple brain regions obtained from three independent 
cohorts implicates a role for cortex-specific hypermethylation across a region within ANK1 
in AD-associated neuropathology, with methylomic changes mirroring known patterns of 
neuropathology and being most significant in the EC. This finding is strengthened by the 
independent identification of the same DMR in another large EWAS of AD21. Finally, 
although most brain-identified DMPs, including ANK1, are not detected in blood, we do 
identify multiple AD-associated DNA methylation differences in pre-mortem blood 
samples, many located in the vicinity of genes previously found to be transcriptionally 
altered even in patients with MCI during the early stages of cognitive decline. Our study 
represents the first EWAS of AD employing a sequential replication design across multiple 
tissues, and highlights the power of this approach more broadly for the identification of 
disease-associated DMRs.
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ONLINE METHODS
Subjects and samples
Brain tissue was obtained from three independent sample cohorts, enabling us to take a 
powerful cross-tissue sequential-replication approach to identifying DNA methylation 
differences in AD. Our discovery cohort comprised of entorhinal cortex (EC), superior 
temporal gyrus (STG), prefrontal cortex (PFC), and cerebellum (CER) tissue obtained from 
117 individuals archived in the MRC London Neurodegenerative Disease Brain Bank 
(http://www.kcl.ac.uk/iop/depts/cn/research/MRC-London-Neurodegenerative-Diseases-
Brain-Bank/MRC-London-Neurodegenerative-Diseases-Brain-Bank.aspx). Ethical approval 
for the study was provided by the NHS South East London REC 3. Matched blood samples 
collected prior to death were available for a subset of individuals (Supplementary Tables S1 
and S2) as part of the Alzheimer’s Research UK funded study “Biomarkers of AD 
Neurodegeneration”, with informed consent according to the Declaration of Helsinki (1991). 
For validation purposes STG and PFC tissue was obtained from 144 individuals archived in 
the Mount Sinai Alzheimer’s Disease and Schizophrenia Brain Bank (http://icahn.mssm.edu/
research/labs/neuropathology-and-brain-banking)19 and EC, STG and PFC samples from an 
additional 62 individuals archived in the Thomas Willis Oxford Brain Collection (http://
www.medsci.ox.ac.uk/optima/information-for-patients-and-the-public/the-thomas-willis-
oxford-brain-collection)20. All samples were dissected by trained specialists, snap-frozen 
and stored at −80°C. Further information about the samples is given in Supplementary Table 
S1 and Supplementary Table S2. Genomic DNA was isolated from ~100mg of each 
dissected brain region or whole blood stored in EDTA collection tubes using a standard 
phenol-chloroform extraction method, and tested for degradation and purity prior to 
analysis.
Power
Power calculations for EWAS analyses are difficult given the paucity of existing data for 
brain DNA methylation and limited information about the extent of inter-individual 
variation occurring at individual CpG sites9. As we have previously discussed, studies 
investigating the role of epigenetic dysfunction in complex brain diseases such as AD are in 
their infancy, and no real precedents have yet been set about the optimal sample-sizes 
needed to detect them9. A conservative power calculation using methylome data from this 
and other ongoing studies in our lab11,39–41, suggests we are well-powered to identify DNA 
methylation differences of ~5% between groups for the majority of probes on the Illumina 
450K array based conservatively on a case-control t-test with an array-wide Bonferroni 
threshold and the observed distribution of beta-value variances for the entorhinal cortex data 
set. More importantly, our study represents the largest cross-tissue study of AD using DNA 
from both affected and unaffected brain regions, and the first to employ a sequential 
replication design incorporating three independent study cohorts and two independent 
technologies (Illumina 450K array and bisulfite-pyrosequencing). The striking overlap 
between DMPs identified across our sample cohorts (Fig. 2a), and with those identified by 
De Jager et al.21 (Fig. 2g and Supplementary Fig. S2), suggests our study was adequately 
powered to detect robust AD-associated differences.
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Methylomic profiling
500ng DNA from each sample was sodium bisulfite-treated using the Zymo EZ 96 DNA 
methylation kit (Zymo Research, CA, USA) according to the manufacturer’s standard 
protocol. Samples were assessed using the Illumina Infinium HumanMethylation450K 
BeadChip (Illumina Inc, CA, USA) using a Illumina HiScan System (Illumina, CA, USA). 
All samples were assigned a unique code for the purpose of the experiment and grouped by 
tissue and randomized with respect to sex and disease status to avoid batch effects, and 
processed in batches of four BeadChips. Illumina Genome Studio software was used to 
extract the raw signal intensities of each probe (without background correction or 
normalization).
Data analysis
All computations and statistical analyses were performed using R 3.0.242 and Bioconductor 
2.1343. Signal intensities were imported into R using the methylumi package44 as a 
methylumi object. Initial quality control checks were performed using functions in the 
methylumi package to assess concordance between reported and genotyped gender. Non-
CpG SNP probes on the array were also used to confirm that all four brain regions and 
matched bloods were sourced from the same individual in the London Cohort and two brain 
regions in the Mount Sinai cohort where expected. Data was pre-processed in the R package 
wateRmelon using the dasen function as previously described11. Array data for each of the 
tissues was normalized separately and initial analyses were performed separately by tissue. 
The effects of age and sex were regressed out before subsequent analysis. For identification 
of DMPs specifically altered with respect to neuropathological measures of AD, we 
performed a quantitative analysis where samples were analyzed using linear regression 
models in respect to Braak stage (London N = 117, Mount Sinai N = 144) and amyloid 
burden (Mount Sinai N = 144). We used a two-level strategy for avoiding spurious signals 
due to SNPs rather than DNA methylation differences. Probes with common (MAF > 5%) 
SNPs in the CG or single base extension position or probes that are nonspecific or 
mismapped were flagged and disregarded in the evaluation of our results45. In order to also 
clean up rarer SNPs whilst discarding minimum data, within each tissue, and for each probe, 
we discarded beta values lying more than four times the interquartile range from the mean; 
these extreme outliers are generally the result of polymorphisms. Data was analyzed 
separately in each brain region using linear regression with probes ranked according to P 
value, and Q-Q plots assessed to check for P value inflation (see Supplementary Fig. S5 for 
example). To identify differentially methylated regions (DMRs), we identified spatially 
correlated P values within our data using the Python module comb-p18 to group ≥4 spatially 
correlated CpGs within a 500bp sliding window. The CETS package in R17 was used to 
check whether our top-ranked DMPs were mediated by the effect of differential neuronal 
cell proportions across samples. To identify probes with consistent associations between 
Braak stage and methylation across the three cortical regions, we employed a meta-analysis 
of EC, STG and PFC. P values from the individual region results for each site were 
generated using Fisher’s method and (as a way of controlling for the covariance of the 
samples which come from the same individuals) Brown’s method. Raw data has been 
deposited in GEO under accession number GSE43414.
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Targeted replication using bisulfite pyrosequencing
Bisulfite pyrosequencing was used to quantify DNA methylation across eight individual 
ANK1 CpG sites, including cg05066959 and cg11823178, spanning from 41519302 to 
41519420 within chromosome 8 (hg19). A single amplicon (246bp) was amplified using 
primers designed using the PyroMark Assay Design software 2.0 (Qiagen, UK) 
(Supplementary Table 11a), and sequenced using two sequencing primers to maximize 
coverage across eight CpG sites. DNA methylation was quantified in 62 samples within the 
Oxford replication cohort using the Pyromark Q24 system (Qiagen, UK) following the 
manufacturer’s standard instructions and the Pyro Q24 CpG 2.0.6 software. Data was 
adjusted for the effects of age and sex. An analysis was performed to compare samples with 
Braak scores 0-II to samples with Braak scores V-VI at a) individual CpGs and b) amplicon-
averaged DNA methylation.
Transcript variant analysis
A subset of samples from the London cohort was selected for RNA analyses. RNA was 
extracted from 30mg brain tissue using the Qiagen RNeasy mini kit and those with a 
concentration >90ng/ul and a RNA integrity number (RIN) >7 (N = 36) were used for 
subsequent qRT-PCR (see Supplementary Table S2 for specific samples used in this 
analysis). 20μl cDNA was synthesized from 1300ng total RNA using the SuperScript® 
VILO™ cDNA Synthesis Kit according to the manufacturer’s protocol and diluted five to 
tenfold for PCR, depending on the downstream assay. Off the shelf TaqMan® Gene 
Expression assays (Life Technologies) were purchased for the five housekeeping genes 
(EIF4A2, GAPDH, ACTB, SF3A1, UBC) identified as being most stably expressed in the 
brain using GeNORM (Primer Design, Southampton, UK). At least ten known protein 
coding splice variants for ANK1 have been characterized (Supplementary Fig. S3), and we 
were able to design three custom TaqMan® Gene Expression assays to target (a) variants 
1,2,3 and 4, (b) variants 5, 7 and 10, and (c) variant 9 (Supplementary Table S11b). qRT-
PCR was performed using TaqMan® Gene Expression Mastermix (Life Technologies) for 
each sample in duplicate on an ABI7900HT according to the manufacturer’s protocol. The 
abundance of ANK1 transcript variants was determined by relative quantification to the 
geometric mean of the five housekeeping genes. Data was adjusted for the effect of age and 
sex and linear models used to analyze variant levels with respect to Braak score.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Cortex-specific hypermethylation of ANK1 is correlated with AD-associated 
neuropathology in the brain
Linear regression models demonstrated that a) cg11823178 in ANK1 is the top-ranked 
neuropathology-associated differentially methylated position (DMP) in the EC in the 
London discovery cohort (N = 104). The adjacent probe, cg05066959, is also significantly 
associated with neuropathology. Green bars denote the location of annotated CpG islands. b) 
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EC DNA methylation at both CpG sites is strongly associated with Braak score 
(cg11823178: r = 0.47, t(102) = 5.39, P = 4.59E–7; cg05066959: r = 0.41, t(102) = 5.37, P = 
1.34E–5). c) Both probes are also associated with neuropathology in the other cortical 
regions assessed in the same individuals, being significantly correlated with Braak score in 
the STG (N = 113) (cg11823178: r = 0.37, t(111) = 4.15, P = 6.51E–5; cg05066959: r = 
0.33, t(111) = 3.67, P = 3.78E–4) and the PFC (N = 110) (cg11823178: r = 0.29, t(108) = 
3.12, P = 2.33E–3; cg05066959: r = 0.32, t(108) = 3.52, P = 6.48E–4). d) There is no 
association between DNA methylation and Braak score at either ANK1 probe in the CER (N 
= 108) (cg11823178: r = 0.01, t(106) = 0.082, P = 0.935; cg05066959: r = −0.08, t(106) = 
0.085, P = 0.395), a region largely protected against AD-related neuropathology. e) 
cg11823178 is the top-ranked cross-cortex DMP (Fisher’s χ2(6) = 60.6, P = 3.42E–11), with 
cg05066959 also strongly associated with Braak score (Fisher’s χ2(6) = 52.9, P = 1.24E–9).
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FIGURE 2. Neuropathology-associated DMPs are consistent across sample cohorts, with 
replicated evidence for ANK1 hypermethylation
a) Braak-associated DNA methylation scores for the top-ranked cross-cortex DMPs 
identified using linear regression models in the London discovery cohort (listed in 
Supplementary Table S9) are significantly correlated with neuropathology-associated 
differences at the same probes in both cortical regions profiled in the Mount Sinai 
replication cohort using linear regression models (PFC (N =142) Braak score: r = 0.64, P = 
6.03E–13; STG (N = 144) Braak score: r = 0.63, P = 2.66E–12; PFC amyloid burden: r = 
0.65, P = 2.87E–13; STG amyloid burden: r = 0.46, P = 1.09E–6). Shown is data for Mount 
Sinai PFC Braak score analysis, with the two ANK1 probes (cg11823178 and cg05066959) 
highlighted in red. cg11823178 and cg05066959 are significantly associated with b) Braak 
score in the STG (cg11823178: r = 0.28, t(142) = 3.62, P = 1.63E–04; cg05066959: r = 0.25, 
t(142) = 3.29, P = 5.78E–04) and PFC (cg11823178: r = 0.24, t(140) = 3.14, P = 1.07E–03; 
cg05066959: r = 0.21, t(140) = 2.75, P = 4.00E–03) and also c) amyloid pathology in the 
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STG (cg11823178: r = 0.21, t(142) = 2.81, P = 4.99E–04; cg05066959: r = 0.27, t(142) = 
3.47, P =5.65E–04) and PFC (cg11823178: r = 0.29, t(140) = 3.69, P = 2.35E–04; 
cg05066959: r = 0.19, t(140) = 2.56, P = 9.93E–03). In the Oxford replication cohort, 
bisulfite–pyrosequencing was used to quantify DNA methylation across eight CpG sites 
spanning an extended ANK1 region. Linear models, adjusting for age and gender, confirmed 
significant neuropathology-associated hypermethylation in all three cortical regions assessed 
(see Supplementary Fig. S1), d) most notably in the EC (N=51), where six of the eight CpG 
sites showed a significant (amplicon average P = 0.0004) neuropathology-associated 
increase in DNA methylation (data is represented as mean +/− SEM, with *=p<0.05, 
**=p<0.01, and ***=p<0.005). Meta-analyses across the three sample cohorts (London, 
Mount Sinai and Oxford) confirms Braak-associated cortex-specific hypermethylation for 
both e) cg11823178 and f) cg05066959. Finally, there is striking consistency in 
neuropathology-associated DMPs identified in our discovery cohort and those identified in 
the co-submitted study by De Jager and colleagues. g) Braak-associated DNA methylation 
scores for the 100 top-ranked cross-cortex DMPs identified in the London discovery cohort 
are significantly correlated with neuropathology-associated differences (neuritic-plaque 
load) at the same probes in the dorsolateral prefrontal cortex (DLPFC) identified by De 
Jager and colleagues in 708 individuals (r = 0.57, P = 1.55E–9)21. The two ANK1 probes 
(cg11823178 and cg05066959) are highlighted in red.
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